Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Intervacc AB's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was €-0.01.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.02.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 34.30% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was -1.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Intervacc AB's EPS without NRI or its related term are showing as below:
FRA:2E9'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.3 Med: -6.4 Max: 34.3
Current: 34.3
During the past 12 years, Intervacc AB's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 34.30% per year. The lowest was -50.30% per year. And the median was -6.40% per year.
FRA:2E9's 3-Year EPS without NRI Growth Rate is ranked better than 71.06% of 1168
companies
in the Biotechnology industry
Industry Median: 16.4
vs FRA:2E9: 34.30
Intervacc AB's EPS (Diluted) for the
three
months ended in Mar. 2026 was €-0.01.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.02.
Intervacc AB's EPS (Basic) for the
three
months ended in Mar. 2026 was €-0.01.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.02.
Intervacc AB (FRA:2E9) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Intervacc AB EPS without NRI Related Terms
Intervacc AB EPS without NRI Historical Data
* Premium members only.
The historical data trend for Intervacc AB's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2E9 vs VRTX, REGN, ALNY: EPS without NRI Comparison
For the Biotechnology subindustry, Intervacc AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intervacc AB PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intervacc AB's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Intervacc AB's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intervacc AB (FRA:2E9) has a EPS without NRI of €-0.02 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Intervacc AB and its competitors. According to the industry distribution chart, Intervacc AB ranks #338 out of 1168 companies in the Biotechnology industry, placing it in the top 28.9%.
Is Intervacc AB's EPS without NRI too high?
Intervacc AB's current EPS without NRI is €-0.02. Based on the distribution chart, Intervacc AB ranks #338 out of 1168 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Intervacc AB has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Intervacc AB's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intervacc AB ranks #338 out of 1168 companies for EPS without NRI. This puts Intervacc AB in the upper half of its industry. The industry median EPS without NRI is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Intervacc AB and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intervacc AB's current EPS without NRI is €-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intervacc AB stock overvalued right now?
Intervacc AB (FRA:2E9) has a current EPS without NRI of €-0.02. The stock's GF Value™ is €0.09, compared to a current price of €0.09 — trading 0.3% below its estimated fair value. The current EPS without NRI is €-0.02. Intervacc AB's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Intervacc AB (FRA:2E9), the current EPS without NRI is €-0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intervacc AB (FRA:2E9) Overvalued in 2026?
Based on GuruFocus' analysis, Intervacc AB stock appears to be undervalued.
The current stock price of €0.09 is trading 0.3% below its estimated GF Value™ of €0.09.
Key valuation signals for FRA:2E9:
EPS without NRI: €-0.02
GF Value™: €0.09 vs. price of €0.09 (0.3% below fair value)
No single metric tells the full story. See the FRA:2E9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
63GF Score
Get the complete analysis for FRA:2E9
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2E9 has been successfully added to your 
